Regenerative Medical Technology (RMTG) EBT Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly EBT Margin of 74.29% for Q1 2026, down 1852.0% year-over-year from 4.24% in Q1 2025, and up 49.53% quarter-over-quarter from 147.2% in Q4 2025.
Regenerative Medical Technology (RMTG) EBT Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology's EBT Margin history runs 9 years deep, the most recent figure standing at 74.29% for Q1 2026.
- In Q1 2026, EBT Margin fell 1852.0% year-over-year to 74.29%; the TTM figure through Mar 2026 stood at 149.28% (down 5557.0% YoY), while the FY2025 annual figure was 168.26%, down 2397.0% from the prior year.
- EBT Margin for Q1 2026 stood at 74.29%, up from 147.2% in the prior quarter.
- The five-year high for EBT Margin was 767.23% in Q4 2023, with the low at 563.32% in Q1 2022.
- The 5-year median for EBT Margin is 147.2% (2025), against an average of 172.78%.
- Peak annual rise in EBT Margin reached 1006704 bps in 2022, while the deepest fall reached 89426 bps in 2022.
- Regenerative Medical Technology's EBT Margin stood at 433.93% in 2022, then surged by 277 bps to 767.23% in 2023, then slumped by 106 bps to 42.3% in 2024, then tumbled by 248 bps to 147.2% in 2025, then surged by 50 bps to 74.29% in 2026.
- Business Quant data shows RMTG's EBT Margin at 74.29% in Q1 2026, 147.2% in Q4 2025, and 333.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 35.71% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -528.97% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 18.33% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 13.77% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -2.67% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 12.09% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -25.06% |
| 10 | Regenerative Medical Technology | 961,772.49 | -99,675.51 | 1.77 Mn | -74.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -74.29% |
| Dec 31, 2025 | -147.20% |
| Sep 30, 2025 | -333.47% |
| Jun 30, 2025 | -132.73% |
| Mar 31, 2025 | -55.77% |
| Dec 31, 2024 | -42.30% |
| Sep 30, 2024 | -89.82% |
| Jun 30, 2024 | -261.67% |
| Mar 31, 2024 | -239.83% |
| Dec 31, 2023 | 767.23% |
| Sep 30, 2023 | -267.87% |
| Jun 30, 2023 | -119.98% |
| Mar 31, 2023 | -73.49% |
| Dec 31, 2022 | -433.93% |
| Sep 30, 2022 | -365.74% |
| Jun 30, 2022 | -503.09% |
| Mar 31, 2022 | -563.32% |
| Dec 31, 2021 | 460.33% |
| Sep 30, 2021 | -6,007.83% |
| Jun 30, 2021 | -4,407.18% |